Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers
Arrowhead Pharmaceuticals Inc ARWR
News
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress
People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
Arrowhead Gets FDA Breakthrough Therapy Designation for Severe Hypertriglyceridemia Drug
Arrowhead Pharmaceuticals Gets FDA Approval for Treatment for Familial Chylomicronemia Syndrome
United States